Trinity Bivalacqua, MD, PhD, announces an upcoming UroView series highlighting key information presented at ASCO 2024 surrounding treatment of high-risk BCG-unresponsive NMIBC.
Deep Data Dive: Highlights From ASCO 2024 on the Treatment of High-Risk BCG-Unresponsive NMIBC
Advertisement
Advertisement
Trending on Urology Times
1
Choosing salvage therapy after prostate cancer focal ablation
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
4
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
5
